LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article: Hepatic venous outflow obstruction: three similar syndromes.

Bayraktar, Ulas-Darda / Seren, Soley / Bayraktar, Yusuf

2007 Volume 13, Issue 13, Page(s) 1912–1927

Abstract: Our goal is to provide a detailed review of veno-occlusive disease (VOD), Budd-Chiari syndrome (BCS), and congestive hepatopathy (CH), all of which results in hepatic venous outflow obstruction. This is the first article in which all three syndromes have ...

Abstract	Our goal is to provide a detailed review of veno-occlusive disease (VOD), Budd-Chiari syndrome (BCS), and congestive hepatopathy (CH), all of which results in hepatic venous outflow obstruction. This is the first article in which all three syndromes have been reviewed, enabling the reader to compare the characteristics of these disorders. The histological findings in VOD, BCS, and CH are almost identical: sinusoidal congestion and cell necrosis mostly in perivenular areas of hepatic acini which eventually leads to bridging fibrosis between adjacent central veins. Tender hepatomegaly with jaundice and ascites is common to all three conditions. However, the clinical presentation depends mostly on the extent and rapidity of the outflow obstruction. Although the etiology and treatment are completely different in VOD, BCS, and CH; the similarities in clinical manifestations and liver histology may suggest a common mechanism of hepatic injury and adaptation in response to increased sinusoidal pressure.
MeSH term(s)	Budd-Chiari Syndrome/etiology ; Budd-Chiari Syndrome/pathology ; Budd-Chiari Syndrome/therapy ; Hepatic Veno-Occlusive Disease/etiology ; Hepatic Veno-Occlusive Disease/pathology ; Hepatic Veno-Occlusive Disease/therapy ; Humans ; Liver Diseases/etiology ; Liver Diseases/pathology ; Liver Diseases/therapy ; Necrosis/pathology ; Prognosis ; Syndrome
Language	English
Publishing date	2007-01-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2185929-2
ISSN	2219-2840 ; 1007-9327
ISSN (online)	2219-2840
ISSN	1007-9327
DOI	10.3748/wjg.v13.i13.1912
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6039: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Advances in haploidentical stem cell transplantation.

Bayraktar, Ulas Darda / de Lima, Marcos / Ciurea, Stefan Octavian

Revista brasileira de hematologia e hemoterapia

2012 Volume 33, Issue 3, Page(s) 237–241

Abstract: Hematopoietic stem cell transplantation from haploidentical donors is an attractive method of transplantation due to the immediate donor availability, ease of stem cell procurement and the possibility to collect additional donor cells for cellular ... ...

Abstract	Hematopoietic stem cell transplantation from haploidentical donors is an attractive method of transplantation due to the immediate donor availability, ease of stem cell procurement and the possibility to collect additional donor cells for cellular therapy, if needed. Historically, maintaining T-cells in the graft has been associated with very high rates of graft-versus-host disease, while T-cell depleted haploidentical transplantation has been limited by a higher incidence of graft rejection and delayed immune reconstitution post-transplant. Recent approaches attempt to maintain the T-cells in the graft while effectively preventing the development of graft-versus-host disease post-transplant. Selective depletion of alloreactive T-cells post-transplant using high-dose post-transplant cyclophosphamide is under investigation as a promising alternative in haploidentical transplantation. While engraftment has improved and graft-versus-host disease is controlled with this approach, future directions should focus on optimizing conditioning regimens and the prevention of disease relapse post-transplant.
Language	English
Publishing date	2012-09-20
Publishing country	Brazil
Document type	Journal Article
ZDB-ID	2105177-X
ISSN	1806-0870 ; 1516-8484
ISSN (online)	1806-0870
ISSN	1516-8484
DOI	10.5581/1516-8484.20110060
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.

Bayraktar, Soley / Bayraktar, Ulas Darda / Rocha-Lima, Caio Max

World journal of gastroenterology

2010 Volume 16, Issue 6, Page(s) 673–682

Abstract: In spite of advances made in the management of the other more common cancers of the gastrointestinal tract, significant progress in the treatment of pancreatic cancer remains elusive. Nearly as many deaths occur from pancreatic cancer as are diagnosed ... ...

Abstract	In spite of advances made in the management of the other more common cancers of the gastrointestinal tract, significant progress in the treatment of pancreatic cancer remains elusive. Nearly as many deaths occur from pancreatic cancer as are diagnosed each year reflecting the poor prognosis typically associated with this disease. Until recently, the only treatment with an impact on survival was surgery. In the palliative setting, gemcitabine (Gem) has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil. Since then, clinical trials have explored the pharmacokinetic modulation of Gem by fixed dose administration and the combination of Gem with other cytotoxic or the biologically "targeted" agents. However, promising trial results in small phase II trials have not translated into survival improvements in larger phase III randomized trials in the advanced disease setting. Two trials have recently reported modest survival improvements with the use of combination treatment with Gem and capecitabine (United Kingdom National Cancer Research GEMCAP trial) or erlotinib (National Cancer Institute of Canada Clinical Trials Group PA.3 trial). This review will focus on the use of systemic therapy for advanced and metastatic pancreatic cancer, summarizing the results of several recent clinical trials and discuss their implications for clinical practice. We will also discuss briefly the second-line chemotherapy options for advanced pancreatic cancer.
MeSH term(s)	Antimetabolites, Antineoplastic/therapeutic use ; Capecitabine ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Disease Progression ; Drug Therapy/trends ; Fluorouracil/analogs & derivatives ; Fluorouracil/therapeutic use ; Humans ; Palliative Care/trends ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/pathology ; Pancreatic Neoplasms/secondary ; Gemcitabine
Chemical Substances	Antimetabolites, Antineoplastic ; Deoxycytidine (0W860991D6) ; Capecitabine (6804DJ8Z9U) ; Fluorouracil (U3P01618RT) ; Gemcitabine
Language	English
Publishing date	2010-01-12
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2185929-2
ISSN	2219-2840 ; 1007-9327
ISSN (online)	2219-2840
ISSN	1007-9327
DOI	10.3748/wjg.v16.i6.673
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6039: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma.

Bayraktar, Ulas Darda / Warsch, Sean / Pereira, Denise

American journal of hematology

2011 Volume 86, Issue 2, Page(s) 224–227

Abstract: One-fifth of the newly diagnosed multiple myeloma (MM) patients present with renal failure (RF) [1-3]. Glucocorticoids (GCs) may improve RF in MM by (1) rapid reduction of paraprotein production, (2) lessening inflammation and fibrosis in renal ... ...

Abstract	One-fifth of the newly diagnosed multiple myeloma (MM) patients present with renal failure (RF) [1-3]. Glucocorticoids (GCs) may improve RF in MM by (1) rapid reduction of paraprotein production, (2) lessening inflammation and fibrosis in renal parenchyma, and (3) decreasing serum calcium level. We hypothesized that lower dose GCs may be less effective in restoring renal function and retrospectively compared the RF reversibility between the newly diagnosed MM patients who were treated with GCs equivalent to ≥160 mg DX over 4 days (high-dose GC group, n = 16) versus those who were treated with <160 mg (low-dose/no GC group, n = 8). There was no difference in age, baseline calcium, and creatinine levels between the two groups. Renal function was restored in seven patients in the high-dose GC group (44%) and in none of the patients in the low-dose/no GC group (P = 0.026). The only other factor found to impact the RF reversibility was the delay of GC initiation. Four and 1 patients developed a severe infection in the high- and low-dose/no GC groups, respectively. The use of higher dose GCs in the newly diagnosed MM patients who present with RF increases the likelihood of renal function restoration.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Dose-Response Relationship, Drug ; Female ; Glucocorticoids/administration & dosage ; Glucocorticoids/therapeutic use ; Humans ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/prevention & control ; Male ; Middle Aged ; Multiple Myeloma/complications ; Multiple Myeloma/drug therapy ; Renal Insufficiency/complications ; Renal Insufficiency/drug therapy ; Retrospective Studies ; Survival Analysis ; Time Factors
Chemical Substances	Glucocorticoids ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2011-02
Publishing country	United States
Document type	Comparative Study ; Journal Article
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.21922
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.

Bayraktar, Ulas Darda / Domingo, Gelenis Calzadilla / Schmit, Jessica / Pereira, Denise

Leukemia & lymphoma

2011 Volume 52, Issue 5, Page(s) 913–915

MeSH term(s)	Adult ; Aged ; Aminoglycosides/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Azacitidine/therapeutic use ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Middle Aged ; Remission Induction/methods ; Retrospective Studies ; Salvage Therapy/methods ; Young Adult
Chemical Substances	Aminoglycosides ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; gemtuzumab (93NS566KF7) ; Azacitidine (M801H13NRU)
Language	English
Publishing date	2011-03-21
Publishing country	United States
Document type	Letter
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.3109/10428194.2010.551570
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Advances in haploidentical stem cell transplantation

Ulas Darda Bayraktar / Marcos de Lima / Stefan Octavian Ciurea

Revista Brasileira de Hematologia e Hemoterapia, Vol 33, Iss 3, Pp 237-

2011 Volume 241

Abstract	Hematopoietic stem cell transplantation from haploidentical donors is an attractive method of transplantation due to the immediate donor availability, ease of stem cell procurement and the possibility to collect additional donor cells for cellular therapy, if needed. Historically, maintaining T-cells in the graft has been associated with very high rates of graft-versus-host disease, while T-cell depleted haploidentical transplantation has been limited by a higher incidence of graft rejection and delayed immune reconstitution post-transplant. Recent approaches attempt to maintain the T-cells in the graft while effectively preventing the development of graft-versus-host disease post-transplant. Selective depletion of alloreactive T-cells post-transplant using high-dose post-transplant cyclophosphamide is under investigation as a promising alternative in haploidentical transplantation. While engraftment has improved and graft-versus-host disease is controlled with this approach, future directions should focus on optimizing conditioning regimens and the prevention of disease relapse post-transplant.
Keywords	Hematopoietic stem cell transplantation ; Hematologic neoplasms ; Bone marrow transplantation ; T-lymphocytes ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Internal medicine ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Subject code	610
Language	English
Publishing date	2011-06-01T00:00:00Z
Publisher	Sociedade Brasileira de Hematologia e Hemoterapia
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Successful treatment of anal gland adenocarcinoma with combined modality therapy.

Warsch, Sean / Bayraktar, Ulas Darda / Wen, B-Chen / Zeitouni, Joseph / Marchetti, Floriano / Rocha-Lima, Caio Max S / Montero, Alberto J

Gastrointestinal cancer research : GCR

2012 Volume 5, Issue 2, Page(s) 64–66

Language	English
Publishing date	2012-06-12
Publishing country	United States
Document type	Case Reports
ZDB-ID	2483324-1
ISSN	1934-7987 ; 1934-7987
ISSN (online)	1934-7987
ISSN	1934-7987
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Comparison of cancer care and outcomes between a public safety-net hospital and a private cancer center.

Bayraktar, Ulas Darda / Warsch, Sean / Chen, Emerson / Lima, Caio Max / Pereira, Denise

Journal of health care for the poor and underserved

2013 Volume 24, Issue 3, Page(s) 1136–1149

Abstract: We compared the cancer outcomes and care-associated service defects between Jackson Memorial Hospital (ABC), a large public safety-net hospital, and Sylvester Comprehensive Cancer Center (XYZ), a private not-for-profit cancer center in patients with ... ...

Abstract	We compared the cancer outcomes and care-associated service defects between Jackson Memorial Hospital (ABC), a large public safety-net hospital, and Sylvester Comprehensive Cancer Center (XYZ), a private not-for-profit cancer center in patients with stage II-III colorectal cancer (CC) who received adjuvant chemotherapy (AC) and in patients with diffuse large B cell lymphoma (DLBCL). Colorectal cancer patients treated at ABC were more likely to have undergone urgent surgery. While in the CC cohort, three-year overall survival and relapse-free survival rates were significantly higher among patients treated at XYZ compared with those treated at ABC, there was no significant difference between patients treated for DLBCL in the two hospitals. Colorectal cancer patients treated at ABC were more likely to have undergone urgent surgery, to have delays before surgery or during chemotherapy, and to experience a system/patient-related service defect; whereas were less likely to complete a full course of AC.
MeSH term(s)	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cancer Care Facilities ; Colorectal Neoplasms/classification ; Colorectal Neoplasms/drug therapy ; Disease-Free Survival ; Female ; Hospitals, General ; Hospitals, Voluntary ; Humans ; Male ; Middle Aged ; Poverty ; Safety-net Providers ; Treatment Outcome ; Young Adult
Language	English
Publishing date	2013-08
Publishing country	United States
Document type	Comparative Study ; Journal Article
ZDB-ID	1142637-8
ISSN	1548-6869 ; 1049-2089
ISSN (online)	1548-6869
ISSN	1049-2089
DOI	10.1353/hpu.2013.0145
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3605: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 493: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.

Bayraktar, Ulas Darda / Diaz, Luis A / Ashlock, Brittany / Toomey, Ngoc / Cabral, Lisa / Bayraktar, Soley / Pereira, Denise / Dittmer, Dirk P / Ramos, Juan Carlos

Leukemia & lymphoma

2013 Volume 55, Issue 4, Page(s) 786–794

Abstract: Treatment of Epstein-Barr virus (EBV)-related lymphomas with lytic-inducing agents is an attractive targeted approach for eliminating virus-infected tumor cells. Zidovudine (AZT) is an excellent substrate for EBV-thymidine kinase: it can induce EBV lytic ...

Abstract	Treatment of Epstein-Barr virus (EBV)-related lymphomas with lytic-inducing agents is an attractive targeted approach for eliminating virus-infected tumor cells. Zidovudine (AZT) is an excellent substrate for EBV-thymidine kinase: it can induce EBV lytic gene expression and apoptosis in primary EBV+ lymphoma cell lines. We hypothesized that the combination of AZT with lytic-inducing chemotherapy agents would be effective in treating EBV+ lymphomas. We report a retrospective analysis of 19 patients with aggressive EBV+ non-Hodgkin lymphoma, including nine cases of acquired immune deficiency syndrome-associated primary central nervous system lymphoma (AIDS-PCNSL) treated with AZT-based chemotherapy. Our results demonstrate that high-dose AZT-methotrexate is efficacious in treating highly aggressive systemic EBV+ lymphomas in the upfront setting. In primary EBV+ lymphoma cell lines, the combination of AZT with hydroxyurea resulted in synergistic EBV lytic induction and cell death. Further, AZT-hydroxyurea treatment resulted in dramatic responses in patients with AIDS-PCNSL. The combination of AZT with chemotherapy, especially lytic-inducing agents, should be explored further in clinical trials for the treatment of EBV-related lymphomas.
MeSH term(s)	Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Cell Line, Tumor ; Combined Modality Therapy ; Epstein-Barr Virus Infections/complications ; Female ; Herpesvirus 4, Human/drug effects ; Humans ; Lymphoma/diagnosis ; Lymphoma/drug therapy ; Lymphoma/etiology ; Lymphoma/mortality ; Male ; Methotrexate/administration & dosage ; Middle Aged ; Neoplasm Staging ; Remission Induction ; Retrospective Studies ; Tomography, Emission-Computed, Single-Photon ; Tomography, X-Ray Computed ; Treatment Outcome ; Zidovudine/administration & dosage ; Zidovudine/adverse effects ; Zidovudine/therapeutic use
Chemical Substances	Antiviral Agents ; Zidovudine (4B9XT59T7S) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2013-08-28
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1042374-6
ISSN	1029-2403 ; 1042-8194
ISSN (online)	1029-2403
ISSN	1042-8194
DOI	10.3109/10428194.2013.818142
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2997: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer

Soley Bayraktar, Ulas Darda Bayraktar, Caio Max Rocha-Lima

World Journal of Gastroenterology, Vol 16, Iss 6, Pp 673-

2010 Volume 682

Abstract	In spite of advances made in the management of the other more common cancers of the gastrointestinal tract, significant progress in the treatment of pancreatic cancer remains elusive. Nearly as many deaths occur from pancreatic cancer as are diagnosed each year reflecting the poor prognosis typically associated with this disease. Until recently, the only treatment with an impact on survival was surgery. In the palliative setting, gemcitabine (Gem) has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil. Since then, clinical trials have explored the pharmacokinetic modulation of Gem by fixed dose administration and the combination of Gem with other cytotoxic or the biologically “targeted” agents. However, promising trial results in small phase II trials have not translated into survival improvements in larger phase III randomized trials in the advanced disease setting. Two trials have recently reported modest survival improvements with the use of combination treatment with Gem and capecitabine (United Kingdom National Cancer Research GEMCAP trial) or erlotinib (National Cancer Institute of Canada Clinical Trials Group PA.3 trial). This review will focus on the use of systemic therapy for advanced and metastatic pancreatic cancer, summarizing the results of several recent clinical trials and discuss their implications for clinical practice. We will also discuss briefly the second-line chemotherapy options for advanced pancreatic cancer.
Keywords	Adjuvant therapy ; Chemotherapy ; Palliative therapy ; Pancreas cancer ; Radiotherapy ; Diseases of the digestive system. Gastroenterology ; RC799-869 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R ; DOAJ:Gastroenterology ; DOAJ:Medicine (General) ; DOAJ:Health Sciences
Subject code	610
Language	English
Publishing date	2010-02-01T00:00:00Z
Publisher	Baishideng Publishing Group Co. Limited
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED